Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...